Elevai Labs, Inc. Common Stock (ELAB) - Total Assets
Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) holds total assets worth $12.87 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ELAB net asset quality score to measure how much of total assets are equity-financed.
Elevai Labs, Inc. Common Stock - Total Assets Trend (2020–2025)
This chart illustrates how Elevai Labs, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Elevai Labs, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Elevai Labs, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Elevai Labs, Inc. Common Stock's total assets of $12.87 Million consist of 53.4% current assets and 46.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.0% |
| Accounts Receivable | $340.53K | 2.7% |
| Inventory | $95.10K | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.89 Million | 22.5% |
| Goodwill | $977.77K | 7.6% |
Asset Composition Trend (2020–2025)
This chart illustrates how Elevai Labs, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ELAB stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elevai Labs, Inc. Common Stock's current assets represent 53.4% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 42.0% of total assets in 2025, down from 78.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 22.5% of total assets.
Elevai Labs, Inc. Common Stock Competitors by Total Assets
Key competitors of Elevai Labs, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Elevai Labs, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.74 | 3.36 | 2.55 |
| Quick Ratio | 1.72 | 3.36 | 2.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.93 Million | $4.25 Million | $913.05K |
Elevai Labs, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Elevai Labs, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 43.1% |
| Total Assets | $12.87 Million |
| Market Capitalization | $2.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values Elevai Labs, Inc. Common Stock's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Elevai Labs, Inc. Common Stock's assets grew by 43.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Elevai Labs, Inc. Common Stock (2020–2025)
The table below shows the annual total assets of Elevai Labs, Inc. Common Stock from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.87 Million | +43.09% |
| 2024-12-31 | $8.99 Million | +73.28% |
| 2023-12-31 | $5.19 Million | +174.28% |
| 2022-12-31 | $1.89 Million | +184.00% |
| 2021-12-31 | $666.25K | +3814.05% |
| 2020-12-31 | $17.02K | -- |
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the med… Read more